Gene · 4144
MAT2A: methionine adenosyltransferase 2A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. MAT2A: methionine adenosyltransferase 2A. Genes, record 4144. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4144
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P31153 | S-adenosylmethionine synthase isoform type-2 | 395 | 59 | Ensembl, GeneID, HGNC |
Source UniProt
Patents30
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 53340 | P31153 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4787 | P31153 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4787 | P31153 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 50756 | P31153 | Espacenet |
| US 11408034 B2 | 2022-08-09 | 502 | P31153 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 153727 | P31153 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 6615 | P31153 | Espacenet |
| US 10584384 B2 | 2020-03-10 | 502 | P31153 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 1446 | P31153 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 233775 | P31153 | Espacenet |
1 to 10 of 30
See all 30 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,110
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MAT2A papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| R01GM089846 | Role of DNA structural dynamics in mutagenesis and oncogenesis | 5 | 2025 |
| RM1HG008935 | Center for dynamic RNA epitranscriptomes - Renewal | 5 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 4 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 4 | 2025 |
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 4 | 2025 |
| P50AA011999 | Southern California Research Center for ALPD and Cirrhosis | 4 | 2025 |
| P50CA127001 | SPORE in Brain Cancer | 4 | 2025 |
| R01AI123165 | Mechanisms of KSHV posttranscriptional gene regulation | 4 | 2025 |
1 to 10 of 1,110Source NIH's project files
See all 1,110 nih grantsPapers1,624
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunohistochemistry Resolves Indeterminate MTAP Deletion Calls From Exome Sequencing: A Pan-Cancer Concordance Study. | Mod Pathol | 2026 | 42778110 | PubTator, text mining | PubMed |
| Integrating proteomics and metabolomics to reveal MAT2A for metabolic reprogramming in non-small cell lung cancer cells. | iScience | 2026 | 42733934 | PubTator, text mining | PubMed |
| MTAP loss in non-small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A-PRMT5 axis. | Cancer Treat Rev | 2026 | 42685449 | PubTator, text mining | PubMed |
| Polyamines buffer labile iron to suppress ferroptosis. | Cell | 2026 | 42600612 | PubTator, text mining | PubMed |
| Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers. | J Med Chem | 2026 | 42593918 | PubTator, text mining | PubMed |
| Decoding the Complexity of Hepatocellular Carcinoma: Clinical Challenges and Targeting HuR as a Novel Therapeutic Strategy. | Livers | 2026 | 42583674 | PubTator, text mining | PubMed |
| The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer. | Clin Cancer Res | 2026 | 42507545 | PubTator, text mining | PubMed |
| Immunohistochemical Loss of MTAP as a Diagnostic and Prognostic Surrogate of CDKN2A/B Homozygous Deletion: A Narrative Review. | Diagnostics (Basel) | 2026 | 42449850 | PubTator, text mining | PubMed |
| Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer. | Adv Healthc Mater | 2026 | 42434841 | PubTator, text mining | PubMed |
| NSUN2 integrates glucose and one‑carbon metabolism upstream of Rag GTPase-dependent mTORC1 signaling. | Cell Signal | 2026 | 42425210 | PubTator, text mining | PubMed |
1 to 10 of 1,624
See all 1,624 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4144
GET https://conductscience.org/api/genes/v1/4144/patents?page=2